Table 2.
Stratification analysis of the association between the lnc-LAMC2–1:1 rs2147578 C > G polymorphism and neuroblastoma susceptibility for combined subjects
| Variable | rs2147578 (case/control) | Crude OR | P | Adjusted OR a | P a | |
|---|---|---|---|---|---|---|
| CC | CG/GG | (95% CI) | (95% CI) | |||
| Age, month | ||||||
| ≤ 18 | 35/120 | 91/184 | 1.70 (1.08–2.67) | 0.022 | 1.70 (1.08–2.67) | 0.022 |
| > 18 | 82/174 | 185/332 | 1.18 (0.86–1.63) | 0.302 | 1.18 (0.86–1.62) | 0.312 |
| Gender | ||||||
| Female | 39/130 | 129/211 | 2.04 (1.34–3.10) | 0.0009 | 2.08 (1.37–3.18) | 0.0007 |
| Male | 78/164 | 147/305 | 1.01 (0.73–1.42) | 0.938 | 1.00 (0.72–1.40) | 0.981 |
| Site of origin | ||||||
| Adrenal gland | 43/294 | 110/516 | 1.46 (1.00–2.13) | 0.052 | 1.41 (0.96–2.07) | 0.077 |
| Retroperitoneal region | 31/294 | 56/516 | 1.03 (0.65–1.63) | 0.903 | 1.04 (0.66–1.66) | 0.863 |
| Mediastinum | 32/294 | 77/516 | 1.37 (0.89–2.12) | 0.157 | 1.39 (0.90–2.16) | 0.138 |
| Others | 9/294 | 27/516 | 1.71 (0.79–3.68) | 0.171 | 1.75 (0.81–3.78) | 0.155 |
| Clinical stage | ||||||
| I + II + 4 s | 46/294 | 116/516 | 1.44 (0.99–2.08) | 0.055 | 1.46 (1.01–2.12) | 0.046 |
| III + IV | 68/294 | 143/516 | 1.20 (0.87–1.65) | 0.272 | 1.16 (0.84–1.61) | 0.362 |
a Adjusted for age and gender
OR odds ratio; CI confidence interval
The values were in bold if the 95% CI excluded 1, or P<0.05